Due to increasing healthcare expenditure, advancing vaccine technology, and rising demand for preventive vaccines, especially new COVID-19 vaccines, the Asia-Pacific preventive vaccines market will rise by 12.89% annually with a total addressable market cap of $97.2 billion between 2020 and 2026.
Coronavirus infection has recently infected millions of people all over the world. In certain areas, community transmission has resulted in an increase in global casualties. At present, Big pharma and biopharma are concentrating their efforts on COVID-19 vaccine research and development. The COVID-19 pandemic situation has generated unprecedented demand, and companies are heavily investing in R&D activities, with government support as well as technological advancement to shorten the clinical trial duration and increase production efficiency. The market's growth prospects will be bolstered by the expansion of vaccine manufacturing facilities to meet the rising demand.
Vaccine World Asia Congress 2022 will be the only vaccine-focused platform in Asia that will bring together global partners and regional stakeholders to leverage partnership opportunities, learn about the latest technological advancements and spearhead scientific innovation. The event will play host to the Big Pharmas, International Biopharma, Asian Biopharma, Academic & Research Institutes, Regulatory Authorities, NGOs, Solution Providers, and Technocrats.
With this edition of Vaccine World Asia, we have co-located with Asia-Pacific Vaccine Excellence Awards. If Asia’s vaccine business matters to you, then Vaccine World Asia Congress 2022 is the place to be!
Vaccine World Asia Congress will be the only vaccine focused platform in Singapore for Asia that will bring together global partners and regional stakeholders to leverage partnership opportunities, learn about the latest technological advancements and spearhead scientific innovation. The event will play host to the BIG Pharmas, International Biopharma’s, Asian Biopharmas, Academic & Research Institutes, Regulatory Authorities, NGOs, Solution Providers and Technocrats. If Asia’s vaccines business matters to you, then Vaccine World Asia 2022 is the place to be!
COVID-19 Vaccine Action Plan in Asian Countries
Effective Strategies to Produce and Manufacture COVID-19 Vaccine at Scale and Pace
Ramping Up COVID-19 Vaccine Fill & Finish Capacity
Vaccines for Emerging Viral Diseases
Clinical Trial Results from Next- Gen and New Pipelines in the Industry
New Approaches to Evaluating Vaccine Quality Control & Safety
Production and Tech Transfers to Speed Up Local Vaccine Production
Whole-Microbe & Genetic Approach of Vaccine Development
The Way Forward for Vaccine Development and the Challenges Ahead
GenScript is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
For more information, visit www.genscript.com
Pfanstiehl is the market leader of high purity / low endotoxin-low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all of the leading global biopharmaceutical companies. Pfanstiehl was founded in 1919 and currently celebrating its 102nd anniversary year in 2021. Pfanstiehl is headquartered at Waukegan, IL, USA and has global presence with sales offices in Switzerland for EMEA & in Singapore for APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s excipients are critical components in the majority of the top global blockbuster biopharmaceutical drugs & vaccines which have been administered to thousands of patients around the world. Pfanstiehl’s high purity, low endotoxin and low metals Carbohydrates & Amino acids are known as “best in class” due to their high purity, performance, consistency and quality attributes.
For more information, please visit: www.pfanstiehl.com
USP is an independent non-profit organization that collaborates with the world’s top health and science experts to develop high-quality standards that set the bar for manufacturing and distributing safe and effective medicines, supplements, and food around the globe. Two billion people worldwide have access to quality medicines, dietary supplements, and food as a result of USP’s standards, advocacy and education.
At USP Biologics our primary objective is to keep you at the vanguard of standards that promote the quality of biological medicines. We do this through our rigorous and proven scientific process. And we place the outcome of our process – the physical standard as well as the method or supporting information– into your hands.
We provide a trusted, independent, single source of reliable standards that are available and used globally. Building upon our successes with more traditional biologics including Insulin and Heparin, we engage with thousands of experts, professionals, associations, regulatory agencies, and companies to pave the way for higher standards for the new wave of biologics and biosimilar drugs. It’s logical really: by actively working with the scientific community and making our rigorously researched standards available to the world, we enable you to provide access to quality medicines for all. Through a collaborative process and commitment to quality, our USP’s biologic standards help by delivering key tools and resources to help make critical medicines, such as the insulin family of products, more accessible to the global population.
To assist you in achieving high standards in drug validation and regulatory compliance as well as avoiding potentially costly mistakes, choose our globally renowned scientific approach that has provided trustworthy standards for decades. Logical really. Our process is as robust as the results you will achieve.
So why not talk with us and find out how we can help advance your biologics and biosimilars project with reliable standards?
For more information, please visit: http://www.usp.org/biologics
Present your expertise to the key vaccines stakeholders from developing economies through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.